1117 related articles for article (PubMed ID: 27574421)
1. Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base.
Li F; Zheng C; Xin J; Chen F; Ling H; Sun L; Webster TJ; Ming X; Liu J
Int J Nanomedicine; 2016; 11():3875-90. PubMed ID: 27574421
[TBL] [Abstract][Full Text] [Related]
2. pH-sensitive Au-BSA-DOX-FA nanocomposites for combined CT imaging and targeted drug delivery.
Huang H; Yang DP; Liu M; Wang X; Zhang Z; Zhou G; Liu W; Cao Y; Zhang WJ; Wang X
Int J Nanomedicine; 2017; 12():2829-2843. PubMed ID: 28435261
[TBL] [Abstract][Full Text] [Related]
3. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery.
Wang D; Chen W; Li H; Huang G; Zhou Y; Wang Y; Wan W; You B; Liu Y; Zhang X
Int J Pharm; 2020 Jul; 585():119456. PubMed ID: 32492507
[TBL] [Abstract][Full Text] [Related]
4. Engineered bovine serum albumin-based nanoparticles with pH-sensitivity for doxorubicin delivery and controlled release.
Yang Z; Zhang N; Ma T; Liu L; Zhao L; Xie H
Drug Deliv; 2020 Dec; 27(1):1156-1164. PubMed ID: 32755291
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.
Thao le Q; Byeon HJ; Lee C; Lee S; Lee ES; Choi YW; Choi HG; Park ES; Lee KC; Youn YS
Pharm Res; 2016 Mar; 33(3):615-26. PubMed ID: 26526555
[TBL] [Abstract][Full Text] [Related]
7. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
[TBL] [Abstract][Full Text] [Related]
8. Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug delivery.
Zu Y; Meng L; Zhao X; Ge Y; Yu X; Zhang Y; Deng Y
Int J Nanomedicine; 2013; 8():1207-22. PubMed ID: 23569373
[TBL] [Abstract][Full Text] [Related]
9. BSA-based Cu
Liu Z; Chan L; Ye X; Bai Y; Chen T
Colloids Surf B Biointerfaces; 2018 Dec; 172():298-307. PubMed ID: 30173097
[TBL] [Abstract][Full Text] [Related]
10. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
11. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.
Pan ZZ; Wang HY; Zhang M; Lin TT; Zhang WY; Zhao PF; Tang YS; Xiong Y; Zeng YE; Huang YZ
Acta Pharmacol Sin; 2016 Aug; 37(8):1110-20. PubMed ID: 27292613
[TBL] [Abstract][Full Text] [Related]
12. Biocompatibility studies of intravenously administered ionic-crosslinked chitosan-BSA nanoparticles as vehicles for antitumour drugs.
Montero N; Pérez E; Benito M; Teijón C; Teijón JM; Olmo R; Blanco MD
Int J Pharm; 2019 Jan; 554():337-351. PubMed ID: 30439492
[TBL] [Abstract][Full Text] [Related]
13. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
14. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas.
Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y
Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of doxorubicin-incorporated magnetic albumin nanospheres.
Zeybek A; Şanlı-Mohamed G; Ak G; Yılmaz H; Şanlıer ŞH
Chem Biol Drug Des; 2014 Jul; 84(1):108-15. PubMed ID: 24524300
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
18.
El-Ghareb WI; Swidan MM; Ibrahim IT; Abd El-Bary A; Tadros MI; Sakr TM
Int J Pharm; 2020 Aug; 586():119514. PubMed ID: 32565281
[TBL] [Abstract][Full Text] [Related]
19. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug.
Lee BS; Park K; Park S; Kim GC; Kim HJ; Lee S; Kil H; Oh SJ; Chi D; Kim K; Choi K; Kwon IC; Kim SY
J Control Release; 2010 Oct; 147(2):253-60. PubMed ID: 20624433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
